Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder

Katrine Kveli Fjukstad, MD, Anne Engum, MD, PhD, Stian Lydersen, PhD, Ingrid Dietz, MD, PhD, Nils Eiel Steen, MD, PhD, Ole A. Andreassen, MD, PhD, and Olav Spigset, MD, PhD

Objective: The aim of the present study was to examine the effect of selective serotonin reuptake inhibitors (SSRIs) on cardiovascular risk factors in patients with schizophrenia or bipolar disorder.

Method: We used data from a cross-sectional study on 1301 patients with schizophrenia or bipolar disorder, of whom 280 were treated with SSRIs. The primary outcome variable was the serum concentration of total cholesterol. Secondary outcome variables were low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, triglyceride and glucose levels, body mass index, waist circumference, and systolic and diastolic blood pressure.

Results: After adjusting for potential confounders, an SSRI serum concentration in the middle of the reference interval was associated with an increase of the total cholesterol level by 14.56 mg/dL (95% confidence interval (CI) 5.27–23.85 mg/dL, P = 0.002), the LDL cholesterol level by 8.50 mg/dL (CI 0.22–16.77 mg/dL, P = 0.044), the triglyceride level by 46.49 mg/dL (CI 26.53–66.46 mg/dL, P < 0.001) and the occurrence of the metabolic syndrome by a factor of 2.10 (CI 1.21–3.62, P = 0.008). There were also significant associations between the SSRI dose and total cholesterol and LDL cholesterol levels.

Conclusions: This study is the first to reveal significant associations between SSRI use and metabolic abnormalities in patients with schizophrenia or bipolar disorder. Although the effects were statistically significant, alterations were small. Thus, the clinical impact of the findings is most likely limited.

Key Words: antidepressants, selective serotonin reuptake inhibitors, metabolic abnormalities, schizophrenia, bipolar disorder, antipsychotics

(J Clin Psychopharmacol 2016;36: 615–620)

Subjects

The Thematically Organized Psychoysis (TOP) study at the Oslo University in Norway provides a large, well-described...
sample of patients with schizophrenia spectrum and bipolar disorders. Inclusion criteria consist of meeting DSM-IV criteria for schizophrenia or bipolar disorder, being 18 to 65 years, and being willing and able to give a written, informed consent of participation. A thorough description of the study has been published previously. The TOP study is an ongoing study consecutively including new patients, and at the time of data extraction for the present study, 1301 patients were available (Table 1). The study was approved by the Regional Committee for Medical and Health Research Ethics South East, Norway and by the Norwegian Data Protection Agency. The presence of some cardiovascular risk factors in a subgroup of the TOP sample has been described earlier, primarily related to the type of the underlying disorder.9

**Variables**

As exposure variables for SSRI intake, the daily dose and the serum concentration of the drug were used. To be able to study SSRIs as a group, the daily dose for each subject was expressed as the number of defined daily doses (DDD) taken (10 mg escitalopram; 20 mg citalopram, fluoxetine, and paroxetine; and 50 mg sertraline).28 The analyses of the SSRI serum concentrations were performed at the Department of Clinical Pharmacology, St. Olav University Hospital by means of previously published analytical methods.29 The concentrations of the various SSRIs were related to the reference interval of the respective drug30 and expressed as the measured concentration of the SSRI divided by the middle value of the reference interval for the same drug, ie, 80 ng/mL (reference interval, 50–110 ng/mL) for citalopram, 48 ng/mL (reference interval, 15–80 ng/mL) for escitalopram, 310 ng/mL (reference interval, 120–500 ng/mL) for fluoxetine plus the active metabolite norfluoxetine, 75 ng/mL (reference interval, 30–120 ng/mL) for paroxetine, and 80 ng/mL (reference interval, 10–150 ng/mL) for sertraline. Because of the more definite metabolic effects reported after uses of paroxetine and fluoxetine,22–24,26,27,31–33 subanalyses were performed after excluding these drugs.

The serum concentration of total cholesterol was chosen as the primary outcome variable because this is considered one of the most important factors related to cardiovascular health.34 Secondary outcome variables were LDL cholesterol, HDL cholesterol, triglyceride and glucose levels, BMI, waist circumference, and diastolic and systolic blood pressure. Fasting serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and glucose were analyzed at the Department of Clinical Chemistry, Oslo University Hospital according to standard methods using an Integra 800 instrument (Roche Diagnostics, Basel, Switzerland). Resting blood pressure was measured manually by a physician using a sphygmomanometer (Boso, Jungingen, Germany). Each individual’s height and waist circumference was measured with standard methods, body weight was weighed on calibrated digital weights (Soehnle, Nassau, Germany) with light clothes on, and BMI (kg/m²) was calculated accordingly.

The metabolic syndrome was defined as the presence of 3 or more of the following 5 variables surpassing predefined cutoff levels according to the National Cholesterol Education Program Adult Treatment Panel-III criteria25: waist circumference, HDL cholesterol levels, triglyceride levels, glucose levels, and blood pressure. When defining the occurrence of the metabolic syndrome, the medication criteria were not taken into account because there was only information available for psychotropic medications and not for drugs used for somatic conditions.

**Statistical Analyses**

Missing values were handled as follows: first, missing serum concentrations for the SSRIs (39 for escitalopram, 8 for citalopram, 6 for sertraline and fluoxetine, and 1 for paroxetine) were imputed by single imputation using the expectation

| TABLE 1. Use of SSRIs Related to Demographic Variables, Diagnosis and Outcome Among 1301 Patients Included in the Study, Based on Complete Cases |
|-----------------|------------------|-----------------|------------------|
| **Variables**   | **All Patients** | **Patients Using SSRIs** | **Patients Not Using SSRIs** |
| **Age (y)**     | 31.7 (10.6)      | 31.4 (10.7)      | 31.8 (10.6)      |
| **Sex**         |                  |                  |                  |
| **Males (n)**   | 697 (53.6%)      | 130 (46.4%)      | 567 (55.6%)      |
| **Females (n)** | 604 (46.4%)      | 150 (53.6%)      | 454 (44.5%)      |
| **Diagnosis**   |                  |                  |                  |
| **Bipolar disorder (n)** | 433 (33.3%) | 111 (39.6%) | 322 (31.5%) |
| **Schizophrenia (n)** | 868 (66.7%) | 169 (60.4%) | 699 (68.5%) |

| **Outcome**         | **Numbers Missing** | **All Patients (N = 1301)** | **Patients Using SSRIs (N = 280)** | **Patients Not Using SSRIs (N = 1021)** |
|---------------------|---------------------|-------------------------------|-------------------------------------|-----------------------------------------|
| **Total cholesterol (mg/dL)** | 165 | 198 (41.8) | 205 (44.1) | 197 (41.0) |
| **LDL cholesterol (mg/dL)** | 219 | 122 (37.1) | 126 (40.6) | 121 (36.0) |
| **HDL cholesterol (mg/dL)** | 165 | 52.7 (16.4) | 51.6 (16.5) | 53.0 (16.4) |
| **Triglycerides (mg/dL)** | 168 | 130 (93.9) | 142 (101.9) | 127 (91.2) |
| **Glucose (mg/dL)** | 167 | 92.8 (20.4) | 92.4 (20.4) | 93.0 (20.4) |
| **Waist circumference (in)** | 415 | 36.2 (5.7) | 36.6 (6.2) | 36.1 (5.6) |
| **BMI (mg/m²)** | 106 | 26.2 (5.0) | 26.6 (5.2) | 26.1 (5.6) |
| **Systolic blood pressure (mm Hg)** | 99 | 121 (15.4) | 120 (14.4) | 121 (15.6) |
| **Diastolic blood pressure (mm Hg)** | 103 | 77.6 (10.6) | 77.4 (10.2) | 77.7 (10.7) |

In total, 280 patients (21.5%) were using SSRIs and 1021 (78.5%) were not. Values are mean (SD) or n (%) as appropriate. For variables related to symptom severity, lifestyle factors, and use of concomitant medication, see Supplementary Table A, Supplemental Digital Content 1, http://links.lww.com/JCP/A387.
maximization algorithm separately for each of the 5 substances using the number of DDD of the SSRI, age, and sex as predictors. Second, we used multiple imputation to handle other missing values. Sixty-two variables were imputed, and we imputed 100 data sets as recommended by van Buuren. The imputed dataset consisted of variables included in the analyses (see Table 1 and Supplementary Table A, Supplemental Digital Content 1, http:// links.lww.com/JCP/A387, where the numbers of missing values for each variable are also found). In addition, the following variables, which were considered additional predictors and were added to enhance the quality of the imputation, but were deemed redundant in the analyses (missing numbers in parentheses): height (n = 96), body weight (n = 104), heart rate (n = 149), Calgary Depression Scale for Schizophrenia (n = 402), use of snuff (n = 61), occurrence of diabetes (n = 0) and use of venlafaxine (n = 0), tricyclic antidepressants (n = 0), other antidepressants (n = 0), topiramate (n = 0), and amphetamine (n = 0). Analyses based on imputations with transformed variables gave implausible results and were discarded; we therefore imputed on untransformed variables as recommended by Rodwell et al.66

Linear regression was performed with total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, glucose, BMI, waist circumference, and systolic and diastolic blood pressure as dependent variables. Normality of residuals was assessed by visual inspection of Q-Q plots. The assumption of normality was violated in the case of triglycerides and glucose. Triglycerides were transformed logarithmically and glucose inversely. This provided practically the same results as regression with untransformed variables. All results are therefore presented for untransformed variables.

Potential confounders, listed in Supplementary Table B, Supplemental Digital Content 1, http://links.lww.com/JCP/A387, were added in separate analyses one at a time in a hierarchical manner and included in the final analysis. Results are presented unadjusted as well as adjusted for these confounders. A logistic regression was conducted to investigate the effects of SSRI doses and concentrations on the prevalence of metabolic syndrome, with the results presented as odds ratios (ORs).

Two-sided P values less than 0.05 were considered statistically significant, and 95% confidence intervals (CI) are reported when relevant. Analyses were performed in SPSS version 21 (IBM, Chicago, Ill).

## RESULTS

Of the 1301 patients included, 280 (21.5%) used SSRIs: escitalopram (n = 154), citalopram (n = 51), sertraline (n = 40), fluoxetine (n = 25), paroxetine (n = 8), escitalopram and citalopram (n = 1), and escitalopram and sertraline (n = 1). Demographic and clinical characteristics of the patients are presented in Table 1 and Supplementary Table A, Supplemental Digital Content 1, http:// links.lww.com/JCP/A387. In total, 76.4% of the patients treated with SSRIs and 72.7% of the patients not using SSRIs were prescribed antipsychotic drugs.

Results of regression analyses for total cholesterol level related to the dose and the serum concentration of the SSRIs are presented in Table 2. After adjusting for all potential confounders, for each DDD of an SSRI taken per day, the total cholesterol level was increased by 3.94 mg/dL (CI 3.57–7.50 mg/dL, P = 0.032). A serum SSRI concentration in the middle of the reference interval was associated with a 14.56 mg/dL (CI 5.27–23.85 mg/dL, P = 0.002) increase in total cholesterol level compared with an SSRIs concentration of 0 (ie, not using any SSRIs). To visualize the results in absolute terms, the impact of SSRI use related to dose in a 30-year-old woman is presented in Supplementary Figure 1, Supplemental Digital Content 1, http:// links.lww.com/JCP/A388.

Associations with LDL cholesterol, HDL cholesterol, triglycerides, glucose, waist circumference, BMI, and blood pressure are presented in Table 3. The LDL cholesterol association was statistically significant for both SSRI dose and SSRI serum concentration after adjusting for potential confounders. In the cases of triglycerides, associations were significant when related to the SSRI serum concentration but not to the SSRI dose. Adding BMI as a covariate did not affect the outcome variables.

The SSRI serum concentration was significantly associated with occurrence of the metabolic syndrome (unadjusted OR 1.97, CI 1.12–3.27, P = 0.008; OR after adjustment for all potential confounders 2.10, CI 1.21–3.62, P = 0.008). In contrast, no significant association was found between SSRI dose and the metabolic syndrome (unadjusted OR 1.16, CI 0.79–1.40, P = 0.100; adjusted OR 1.16, CI 0.49–1.41, P = 0.150).

When excluding patients using fluoxetine and paroxetine, SSRI serum concentrations were still significantly associated with total cholesterol, LDL cholesterol, and triglyceride levels (Supplementary Table C, Supplemental Digital Content 1, http://links.lww.com/JCP/A389). However, the magnitude of the association was smaller for fluoxetine.

### TABLE 2. Linear Regression With Serum Concentrations or Doses of SSRIs as Independent Variables, and Serum Levels of Total Cholesterol (in mg/dL) as Dependent Variable, in 1301 Patients With Bipolar Disorder or Schizophrenia

| Effect on Serum Cholesterol Level (mg/dL) | Related to SSRI Serum Concentration* | Related to SSRI Dose† |
|------------------------------------------|--------------------------------------|-----------------------|
|                                           | B                                  | CI                    | P          | B          | CI          | P         |
| Unadjusted                               | 13.50                              | 3.93–23.07            | 0.006      | 3.63       | 0.00–7.27   | 0.050     |
| Adjusted for age                         | 13.71                              | 4.56–22.86            | 0.003      | 4.02       | 0.54–7.50   | 0.024     |
| Adjusted for sex                         | 13.99                              | 4.39–23.58            | 0.004      | 3.71       | 0.08–7.35   | 0.045     |
| Adjusted for age and sex                 | 14.55                              | 5.83–23.71            | 0.002      | 4.18       | 0.70–7.66   | 0.019     |
| Adjusted for all potential confounders‡  | 14.56                              | 5.27–23.85            | 0.002      | 3.94       | 0.35–7.50   | 0.032     |

Results are presented as regression coefficients (B) with 95% CI and P values.

*The calculated effect is that represented by a serum concentration in the middle of the reference interval for each drug. For details, see “Materials and Methods” section.

†The calculated effect is that represented by a serum concentration in the middle of the reference interval for each drug. For details, see “Materials and Methods” section and Supplementary Table B, Supplemental Digital Content 1, http://links.lww.com/JCP/A387.

‡Adjusted for all potential confounders. For details, see “Materials and Methods” section and Supplementary Table B, Supplemental Digital Content 1, http://links.lww.com/JCP/A387.
TABLE 3. Linear Regression With Serum Concentrations or Doses of SSRIs as Independent Variables and Serum Levels of LDL Cholesterol, HDL Cholesterol, Triglycerides, Glucose, Waist Circumference, BMI, or Blood Pressure as Dependent Variables, in 1301 Patients With Bipolar Disorder or Schizophrenia

| Dependent Variable | Independent Variable | Unadjusted | Adjusted* |
|--------------------|----------------------|------------|-----------|
|                    |                      | B          | CI        | P      |
| LDL cholesterol (mg/dL) | SSRI serum concentration† | 6.19 | -2.27–14.64 | 0.152 |
|                    | SSRI dose †         | 2.82 | -0.39–5.99  | 0.083 |
| HDL cholesterol (mg/dL) | SSRI serum concentration† | -1.98 | -5.73–1.78  | 0.302 |
|                    | SSRI dose †         | -1.08 | -2.47–0.35  | 0.134 |
| Triglycerides (mg/dL) | SSRI serum concentration† | 45.87 | 25.65–66.09 | <0.001 |
|                    | SSRI dose †         | 8.41 | 0.89–16.03  | 0.029 |
| Glucose (mg/dL) | SSRI serum concentration† | -2.39 | -6.84–2.06  | 0.293 |
|                    | SSRI dose †         | -0.76 | -2.41–0.92  | 0.379 |
| Waist circumference (in) | SSRI serum concentration† | 0.80 | -0.49–2.09  | 0.225 |
|                    | SSRI dose †         | 0.29 | -0.15–0.73  | 0.201 |
| BMI (kg/m²) | SSRI serum concentration† | 0.77 | -0.26–1.79  | 0.144 |
|                    | SSRI dose †         | 0.28 | -0.09–0.66  | 0.142 |
| Systolic blood pressure (mm Hg) | SSRI serum concentration† | -1.43 | -4.69–1.84  | 0.392 |
|                    | SSRI dose †         | -0.52 | -1.71–0.68  | 0.397 |
| Diastolic blood pressure (mm Hg) | SSRI serum concentration† | 0.32 | -1.95–2.58  | 0.784 |
|                    | SSRI dose †         | -0.06 | -0.89–0.77  | 0.888 |

Results are presented as regression coefficients (B) with 95% CI and P values. Statistically significant values are displayed in bold.

*Adjusted for all potential confounders. For details, see “Materials and Methods” section and Supplementary Table B, Supplemental Digital Content 1, http://links.lww.com/JCP/A387.
†The calculated effect is that represented by a serum concentration in the middle of the reference interval for each drug. For details, see “Materials and Methods” section.
‡The calculated effect is that represented by a daily dose of 10 mg escitalopram, 20 mg citalopram, 20 mg fluoxetine, 20 mg paroxetine, or 50 mg sertraline.

http://links.lww.com/JCP/A387). In addition, there were significant associations with waist circumference and BMI. Associations between the individual drugs citalopram, escitalopram, and sertraline and the metabolic variables are also presented in Supplementary Table C, Supplemental Digital Content 1, http://links.lww.com/JCP/A387.

DISCUSSION

In this naturalistic study of patients with bipolar disorder or schizophrenia, there were significant associations between SSRI serum concentrations and total cholesterol, LDL cholesterol, and triglyceride levels as well as the risk of the metabolic syndrome. We also found significant associations between SSRI dose and total cholesterol and LDL cholesterol levels.

Our results are mostly in line with previous findings related to SSRI treatment in patients with depression and anxiety.19–24,26,27 In these studies, effects have been most consistent for total cholesterol and LDL cholesterol. In contrast, effects on triglyceride levels, body weight/BMI, and waist circumference vary across studies. The lack of significant effects on glucose levels and blood pressure in the present study is in line with the findings in previous studies.26,27

Subanalyses were performed to investigate potential differences in metabolic disturbances between the individual SSRIs. Paroxetine has been reported to be more strongly associated with metabolic abnormalities than other SSRIs20,22,24,26,27 and fluoxetine has been found to have beneficial effects related to the metabolic syndrome.27 We therefore reanalyzed data after excluding these drugs. Our findings for citalopram, escitalopram, and sertraline are partly consistent and partly inconsistent with the results from previous studies.26,27 These differences can most likely be ascribed to methodological factors, including differences in study design (eg, related to inclusion criteria and follow-up strategies) and statistical issues, such as mass significance and type II errors. It therefore remains unclear whether the subgroup findings reflect true differences between specific SSRIs in various patient groups or are caused by small materials and statistical coincidences.

Some SSRIs have the potential to inhibit the metabolism of certain antipsychotic drugs, thereby increasing the concentration of the antipsychotic and possibly also enhancing its effect on metabolic variables. Such pharmacokinetic interactions are most prominent for fluvoxamine combined with clozapine/olanzapine, but exist also, eg, for fluoxetine/paroxetine plus risperidone and fluoxetine/paroxetine plus clozapine.25 The effects we have found remained, in general, stable irrespective of the specific drug combinations studied. In addition, as numerous SSRI/antipsychotic combinations have been used, most of them with no interacting potential, we consider such an effect to be negligible at the group level. Further testing of possible interaction effects on metabolic variables between SSRIs and antipsychotics is an interesting issue but beyond the scope of this paper.

The fact that we have included the SSRI serum concentration as well as the SSRI dose as exposure variables is considered a strength. Because some effects were related both to SSRI dose and SSRI serum concentration and because the associations generally were stronger when applying the SSRI serum concentration as exposure variable, credibility is added to these associations. The SSRI serum concentration is held to be the criterion standard of the site of action of the drug's pharmacological effect at the site of action in the body. The weaker associations shown by SSRI dose than by SSRI serum concentration are likely to be caused by a combination of variations in adherence and the considerable interindividual
variability in the pharmacokinetics of SSRIs, whereas the SSRI serum concentration bypasses these factors. We also consider it being a strength that we have been able to include more than 1000 patients with extensive information available from each subject, thereby allowing us to adjust for an array of potential confounding factors. The most important factors with this respect include age, sex, diagnosis, lifestyle factors, concomitant treatment with other psychotrophic drugs, and the occurrence of current and previous depression. Consequently, we consider our findings most likely being linked to the SSRI treatment as such.

The weaknesses of the present study are mainly related to its naturalistic and cross-sectional design. Most importantly, causality cannot be proven. Although we have adjusted for numerous potential confounding factors, residual confounding (e.g., caused by somatic diseases, intake of nonpsychotropic medications, and dietary habits) cannot be excluded. The lack of information on concomitant pharmacological treatment for metabolic conditions (e.g., cholesterol-lowering, antidiabetic, and antihypertensive drugs) is an important limitation, particularly related to the risk of misclassification of the metabolic syndrome. In contrast, we consider the risk of bias for the other metabolic variables due to lack of information on treatment with these drugs to be small because the frequency of such treatment would be expected to be similar among those treated and those not treated with SSRIs. Because treatment duration was not taken into consideration, we cannot rule out that some subjects very recently had commenced SSRI treatment. However, this factor would most likely cause an underestimation of the real associations because it could be assumed that the metabolic effects would develop through time.

In conclusion, the present study supports the hypothesis that SSRIs may cause metabolic disturbances. When related to the SSRI serum concentration, we revealed statistically significant but minor effects would develop through time. The weaknesses of the present study are mainly related to its naturalistic and cross-sectional design. Most importantly, causality cannot be proven. Although we have adjusted for numerous potential confounding factors, residual confounding (e.g., caused by somatic diseases, intake of nonpsychotropic medications, and dietary habits) cannot be excluded. The lack of information on concomitant pharmacological treatment for metabolic conditions (e.g., cholesterol-lowering, antidiabetic, and antihypertensive drugs) is an important limitation, particularly related to the risk of misclassification of the metabolic syndrome. In contrast, we consider the risk of bias for the other metabolic variables due to lack of information on treatment with these drugs to be small because the frequency of such treatment would be expected to be similar among those treated and those not treated with SSRIs. Because treatment duration was not taken into consideration, we cannot rule out that some subjects very recently had commenced SSRI treatment. However, this factor would most likely cause an underestimation of the real associations because it could be assumed that the metabolic effects would develop through time.

In conclusion, the present study supports the hypothesis that SSRIs may cause metabolic disturbances. When related to the SSRI serum concentration, we revealed statistically significant but minor increases in total cholesterol, LDL cholesterol, and triglyceride levels as well as a modestly increased risk of the metabolic syndrome. Because of the limited magnitude of the alterations, the clinical impact of the findings is most likely small.

AUTHOR DISCLOSURE INFORMATION
Dr Andreassen has received speaker honoraria from GSK, Lundbeck, and Otsuka. Drs Fjukstad, Engum, Lydersen, Dieten, Steen, and Spigset have no financial interests to declare.

REFERENCES
1. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620–627.
2. Nordentoft M, Wahlbeck K, Hällgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8:e55176.
3. Smith DJ, Martin D, McLean G, et al. Multimorbidity in bipolar disorder. BMJ Open. 2015;5:018614.
4. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23:40–47.
5. Ringen PA, Engh JA, Birkenaes AB, et al. Increased mortality in schizophrenia due to cardiovascular disease—a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry. 2014; 5:137.
6. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66:713–720.
7. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.
8. McElroy SL, Keck PE Jr. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014;75:46–61.
9. Birkenaes AB, Opijordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68:917–923.
10. Taylor V, McKinnon MC, Macdonald K, et al. Adults with mood disorders have an increased risk profile for cardiovascular disease within the first 2 years of treatment. Can J Psychiatry. 2010;55:362–368.
11. Andreassen OA, Djurovic S, Thompson WK, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92: 197–209.
12. Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10:209–216.
13. Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013;125:117–129.
14. Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124:154–167.
15. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68:604–610.
16. Baldessarini RJ, Lehty L, Arconsa S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85–91.
17. Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med. 2014; 44:2017–2028.
18. Bailey DL, Le Mellédo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. J Clin Psychopharmacol. 2003;23:317–319.
19. Kim EJ, Yu BH. Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol. 2005;25: 597–599.
20. Herrán A, Ramírez ML, Carrera M, et al. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol. 2006;26:538–540.
21. Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry. 2003;64: 1455–1459.
22. Wei F, Crain AL, Whitebird RR, et al. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs. 2009;23:857–865.
23. Le Mello DM, Mello ME, Lara N, et al. Paroxetine-induced increase in LDL cholesterol levels. J Psychopharmacol. 2009;23:826–830.
24. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112: 2735–2752.
25. Raeder MB, Bjelland I, Emil Volland S, et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006;67:1974–1982.
26. Beyaz yuz M, Albayrak Y, Egilmez OB, et al. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig. 2013;10:148–154.
28. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2016. Available at http://www.whocc.no/atc_ddd_index/. Accessed April 4, 2016.

29. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42–56.

30. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.

31. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991;24:62–67.

32. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170–1176.

33. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863–867.

34. Shay CM, Gooding HS, Murillo R, et al. Understanding and improving cardiovascular health: an update on the American Heart Association's concept of cardiovascular health. Prog Cardiovasc Dis. 2015;58:41–49.

35. van Buuren S. Flexible Imputation of Missing Data. Boca Raton, FL: CRC Press; 2012.

36. Rodwell L, Lee KJ, Romaniuk H, et al. Comparison of methods for imputing limited-range variables: a simulation study. BMC Med Res Methodol. 2014;14:57.

37. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4–22.